Application of Information Retrieval Approaches to Case Classification in the Vaccine Adverse Event Reporting System

被引：0
|
作者：
Taxiarchis Botsis
Emily Jane Woo
Robert Ball
机构：
[1] US FDA,Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research (CBER)
[2] University of Tromsø,Department of Computer Science
来源：
Drug Safety | 2013年 / 36卷
关键词：
Case Definition; Vector Space Model; Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Spontaneous Reporting System; Vaccine Adverse Event Reporting System;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：573 / 582
页数：9
相关论文
共 36 条
  • [21] Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions
    Eugène P. van Puijenbroek
    Willem L. Diemont
    Kees van Grootheest
    Drug Safety, 2003, 26 : 293 - 301
  • [22] Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018
    Haber, Penina
    Moro, Pedro L.
    Ng, Carmen
    Dores, Graca M.
    Lewis, Paige
    Cano, Maria
    VACCINE, 2019, 37 (11) : 1516 - 1520
  • [23] Safety profile of rotavirus vaccines among individuals aged ≥8 months of age, United States, vaccine adverse event reporting system (VAERS), 2006-2019
    Haber, Penina
    Tate, Jacqueline
    Marquez, Paige L.
    Moro, Pedro L.
    Parashar, Umesh
    VACCINE, 2021, 39 (04) : 746 - 750
  • [24] Adverse event profiles of drugs used for treatment of juvenile idiopathic arthritis according to spontaneous reporting system database
    Niinomi, Iku
    Oyama, Saki
    Inada, Ayaka
    Wakabayashi, Tomohito
    Hirai, Toshinori
    Kambara, Hiroko
    Iida, Tatsuya
    Uchida, Mayako
    Sano, Yukako
    Hosohata, Keiko
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (09) : 402 - 407
  • [25] Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
    Raschi, E.
    Poluzzi, E.
    Koci, A.
    Antonazzo, I. C.
    Marchesini, G.
    De Ponti, F.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2016, 26 (05) : 380 - 386
  • [26] The futility of adverse drug event reporting systems for monitoring known safety issues: A case study of myocardial infarction with rofecoxib and other drugs
    Haguinet, Francois
    Bate, Andrew
    Stegmann, Jens-Ulrich
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [27] Application and evaluation of a classification system and case definitions of Toxoplasma gondii infection
    Stronati, M
    Bollani, L
    Viganò, C
    Lanzarini, P
    Rondini, G
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (01) : 67 - 68
  • [28] Application and evaluation of a classification system and case definitions ofToxoplasma gondii infection
    M. Stronati
    L. Bollani
    C. Viganò
    P. Lanzarini
    G. Rondini
    European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17 : 67 - 68
  • [29] Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system
    Raschi, Emanuel
    Poluzzi, Elisabetta
    Koci, Ariola
    Salvo, Francesco
    Pariente, Antoine
    Biselli, Maurizio
    Moretti, Ugo
    Moore, Nicholas
    De Ponti, Fabrizio
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (02) : 285 - 293
  • [30] Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system
    Hu, Yingying
    Gong, Jian
    Zhang, Lifu
    Li, Xiaolin
    Li, Xina
    Zhao, Bin
    Hai, Xin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 84
1234